title: A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.
abstract: OBJECTIVE
  To assess the real-world efficacy and safety of the first sodium-glucose cotransporter-2 inhibitor, canagliflozin, in the treatment of patients with type 2 diabetes mellitus (T2DM).
  
  
  METHODS
  This observational study assessed the efficacy and tolerability of canagliflozin in T2DM patients. Primary study outcomes were changes in HbA1C and weight, and percentage of patients reporting adverse effects of therapy.
  
  
  RESULTS
  The study criteria were met by 111 patient records. Baseline patient characteristics were: average age, 59 ± 9 years; mean duration of T2DM, 11.9 ± 7.3 years; 57.6% of patients were male; 92.8% were Caucasian; baseline BMI, 38.9 ± 11 kg/m(2); and mean baseline HbA1C, 7.53 (58.8 mmol/mol) ± 1.08%. HbA1C and weight were significantly reduced by 0.37% and 4.4 kg, respectively. Adverse effects were reported by 21 patients, and 17 (15.3%) discontinued canagliflozin because of adverse reactions.
  
  
  CONCLUSIONS
  Canagliflozin was generally well tolerated and significantly reduced HbA1C levels and body weight in patients with T2DM when added to a regimen of other anti-hyperglycemic agents.
authors.affiliation: Albany College of Pharmacy and Health Sciences, Albany, NY.
authors.forename: AnneMarie
authors.initials: A
authors.lastname: Nardolillo
authors.affiliation: Albany College of Pharmacy and Health Sciences, Albany, NY.
authors.forename: Michael P
authors.initials: MP
authors.lastname: Kane
authors.affiliation: The Endocrine Group, LLP, Albany, NY.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Busch
authors.affiliation: The Endocrine Group, LLP, Albany, NY.
authors.forename: Jay
authors.initials: J
authors.lastname: Watsky
authors.affiliation: Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hamilton
keywords: Invokana; SGLT-2 inhibitor; canagliflozin; type 2 diabetes mellitus